Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Bartoli

Showing results (31-40 of 48) with videos related to

Pageof 5
Sort By:
Journal of Personalized Medicine|September 28, 2023
ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical PracticeMaurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Autoimmunity Reviews|October 31, 2021
Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experienceElana Agostini, Giacomo De Luca, Cosimo Bruni, et al.
Journal of Personalized Medicine|July 27, 2024
Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)Maurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Clinical and Experimental Rheumatology|October 3, 2018
The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interactionGinevra Fiori, Tessa Marzi, Francesca Bartoli, et al.
Therapeutic Advances in Musculoskeletal Disease|November 2, 2020
The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseasesCosimo Bruni, Stefano Gentileschi, Giovanni Pacini, et al.
Frontiers in Pediatrics|April 4, 2025
Urinary biomarkers improve prediction of AKI in pediatric cardiac surgeryOscar T Deal, Thomas Mitchell, Amy G Harris, et al.
Annals of the Rheumatic Diseases|March 16, 2007
Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone controlAlberto Pignone, Angela Del Rosso, K Bridget Brosnihan, et al.
Rheumatology (Oxford, England)|May 23, 2020
EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodiesFrancesca Pregnolato, Maria Gerosa, Maria Gabriella Raimondo, et al.
Annals of the New York Academy of Sciences|September 26, 2007
Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosisFrancesca Bartoli, Jelena Blagojevic, Marzia Bacci, et al.
Therapeutic Advances in Musculoskeletal Disease|February 4, 2022
Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysisCosimo Bruni, Stefano Gentileschi, Giovanni Pacini, et al.
Pageof 5

Showing results (31-40 of 48) with videos related to

Sort By:
Pageof 5
Journal of Personalized Medicine|September 28, 2023
ReLiFiRa (Real Life Filgotinib in Rheumatoid Arthritis): Retrospective Study of Efficacy and Safety in Common Clinical PracticeMaurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Autoimmunity Reviews|October 31, 2021
Intravenous immunoglobulins reduce skin thickness in systemic sclerosis: evidence from Systematic Literature Review and from real life experienceElana Agostini, Giacomo De Luca, Cosimo Bruni, et al.
Journal of Personalized Medicine|July 27, 2024
Efficacy and Safety of Filgotinib in Rheumatoid Arthritis Patients Aged over and under 65 Years (ENANTIA-65)Maurizio Benucci, Marco Bardelli, Massimiliano Cazzato, et al.
Clinical and Experimental Rheumatology|October 3, 2018
The challenge of pet therapy in systemic sclerosis: evidence for an impact on pain, anxiety, neuroticism and social interactionGinevra Fiori, Tessa Marzi, Francesca Bartoli, et al.
Therapeutic Advances in Musculoskeletal Disease|November 2, 2020
The switch from etanercept originator to SB4: data from a real-life experience on tolerability and persistence on treatment in joint inflammatory diseasesCosimo Bruni, Stefano Gentileschi, Giovanni Pacini, et al.
Frontiers in Pediatrics|April 4, 2025
Urinary biomarkers improve prediction of AKI in pediatric cardiac surgeryOscar T Deal, Thomas Mitchell, Amy G Harris, et al.
Annals of the Rheumatic Diseases|March 16, 2007
Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone controlAlberto Pignone, Angela Del Rosso, K Bridget Brosnihan, et al.
Rheumatology (Oxford, England)|May 23, 2020
EUREKA algorithm predicts obstetric risk and response to treatment in women with different subsets of anti-phospholipid antibodiesFrancesca Pregnolato, Maria Gerosa, Maria Gabriella Raimondo, et al.
Annals of the New York Academy of Sciences|September 26, 2007
Flow-mediated vasodilation and carotid intima-media thickness in systemic sclerosisFrancesca Bartoli, Jelena Blagojevic, Marzia Bacci, et al.
Therapeutic Advances in Musculoskeletal Disease|February 4, 2022
Switching from originator adalimumab to biosimilar SB5 in a rheumatology cohort: persistence on treatment, predictors of drug interruption and safety analysisCosimo Bruni, Stefano Gentileschi, Giovanni Pacini, et al.
Pageof 5